ArticlePharmacoEconomics - open2024
Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH).
Article in PharmacoEconomics - open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review.PharmacoEconomics · 2025Pooled it
- A Team-Based Patient Engagement Approach to Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension (TEAM PAH): Real-World Dosing Patterns and Persistence Among Patients With and Without a History of Methamphetamine Use.Pulmonary circulation · 2026Article
- Sociodemographic determinants of disease severity in a public healthcare system : Evidence from keratoconus patients in Austria.Wiener klinische Wochenschrift · 2026Article
- Article
- Machine learning for prediction of key haemodynamic parameters in pulmonary arterial hypertension.European heart journal. Digital health · 2026Article
- Healthcare Resource Utilization and Medical Costs in Pulmonary Arterial Hypertension Management in Japan: A Retrospective Study Using a Claims Database.Pulmonary therapy · 2026Article
- Acceptability of Sharing Internet Browsing History for Cancer Research: Think-Aloud and Interview Study.JMIR cancer · 2026Article
- Factors Associated with Referral to Expert Providers among Patients with Pulmonary Hypertension.Annals of the American Thoracic Society · 2025Article
- Impact of treatment escalation on rehospitalization among patients with pulmonary arterial hypertension.Scientific reports · 2025Article
- 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association.Circulation · 2025Review
- Beneath the surface: a narrative review of multidimensional burdens and pathways to patient-centered care in PAH.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to assess health care resource utilization (HRU) and costs associated with delayed pulmonary arterial hypertension (PAH) diagnosis in the United States.
methodsEligible adults with newly diagnosed PAH from Optum's de-identified Clinformatics
resultsAmong 538 patients (mean age: 65.6 years; 60.6% female), 60.8% had ≤12 months' delay, 23.4% had a delay of >12 to ≤24 months, and 15.8% had >24 months' delay. Compared with ≤12 months, delays of >12 to ≤24 months and >24 months were associated with increased hospitalizations (incidence rate ratio [95% confidence interval]: 1.40 [1.11-1.71] vs 1.71 [1.29-2.12]) and outpatient visits (1.17 [1.06-1.30] vs 1.26 [1.08-1.41]). Longer delays were also associated with more intensive care unit (ICU) stays and 30-day readmissions. Diagnosis delays translated into excess costs PPPM of US$3986 [1439-6436] for >12 to ≤24 months and US$5366 [2107-8524] for >24 months compared with ≤12 months' delay; increased hospitalization costs (US$3248 [1108-5135] and US$4048 [1401-6342], respectively) being the driver. Sensitivity analyses yielded similar trends.
conclusionsDelayed PAH diagnosis is associated with significant incremental economic burden post-diagnosis, driven by hospitalizations including ICU stays and 30-day readmissions, highlighting the need for increased awareness and a potential benefit of earlier screening.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.